Favorable Media Coverage Somewhat Unlikely to Affect Natera (NTRA) Share Price

News articles about Natera (NASDAQ:NTRA) have trended positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Natera earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 46.1583120538391 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of Natera (NASDAQ:NTRA) opened at $10.41 on Thursday. The company has a market capitalization of $569.41, a price-to-earnings ratio of -4.25 and a beta of 2.07. Natera has a 12 month low of $7.35 and a 12 month high of $14.76. The company has a debt-to-equity ratio of 2.43, a quick ratio of 1.75 and a current ratio of 1.85.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.51) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.04). The business had revenue of $56.66 million for the quarter, compared to analyst estimates of $55.31 million. Natera had a negative return on equity of 197.09% and a negative net margin of 62.34%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.50) EPS. analysts expect that Natera will post -2.15 earnings per share for the current fiscal year.

Several analysts recently commented on the company. BidaskClub raised Natera from a “sell” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research downgraded Natera from a “hold” rating to a “sell” rating in a research note on Tuesday, January 23rd. Robert W. Baird reaffirmed a “buy” rating on shares of Natera in a research note on Tuesday, October 24th. Cowen reaffirmed a “buy” rating and set a $12.00 price objective on shares of Natera in a research note on Thursday, December 21st. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $15.00 price objective on shares of Natera in a research note on Tuesday, November 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $14.50.

COPYRIGHT VIOLATION WARNING: “Favorable Media Coverage Somewhat Unlikely to Affect Natera (NTRA) Share Price” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/01/favorable-media-coverage-somewhat-unlikely-to-affect-natera-ntra-share-price.html.

Natera Company Profile

Natera, Inc is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother’s blood and a blood sample from the alleged father(s).

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply